tbuckley/cabot-search huggingface dataset:
Radiological evaluation of patients receiving assisted ventilation
Authors: L. R. Goodman
Journal: JAMA (1981)

WITH the increasing use of tracheal intubation and mechanical ventilators for respiratory support, both clinician and radiologist are seeing an increased number of portable roentgenograms of patients receiving assisted ventilation. An understanding of the expected radiological appearance and potential complications should help decrease the frequency of iatrogenic problems in these critically ill patients.<sup>1</sup> <h3>Endotracheal Tube</h3> The ideal location for the tip of the endotracheal tube is 5 to 7 cm from the carina. This places the tip midway between the carina and the vocal cords. When the carina is not visible, its position may be approximated from prior portable films or by using the vertebral bodies as reference markers. On 95% of portable roentgenograms, the carina projects over the fifth, sixth, or seventh thoracic vertebral body.<sup>1</sup> Proper positioning of the tube is important because flexion or extension of the neck moves the endotracheal tube tip relative to the
Abstract 612: Overexpression of PCDHB9 is correlated with tumor progression in esophageal cancer
Authors: Naohide Oue, Yuji Yamamoto, Ryuichi Asai, Naoya Sakamoto, Kazuhiro Sentani, Wataru Yasui
Journal: Cancer Research (2019)

Abstract Genes encoding transmembrane proteins expressed specifically in cancer cell may be ideal biomarkers for diagnosis. Previously, we showed that overexpression of PCDHB9, which was identified as a transmembrane protein, promotes peritoneal metastasis and correlates with poor prognosis in patients with gastric cancer. However, expression of PCDHB9 in esophageal cancer remains unclear. In the present study, we investigated the expression and function of PCDHB9 in esophageal squamous cell carcinoma (ESCC). Immunohistochemical analysis demonstrated that 51 (40%) of 128 GC cases were positive for PCDHB9. PCDHB9 expression was correlated with T classification, N classification and tumor stage. There was no significant correlation between PCDHB9 expression and patient survival. Cell adhesion to fibronectin and invasion activity were significantly reduced by PCDHB9 knockdown. These results suggest that PCDHB9 may be a novel biomarker and therapeutic target for ESCC. Citation Format: Naohide Oue, Yuji Yamamoto, Ryuichi Asai, Naoya Sakamoto, Kazuhiro Sentani, Wataru Yasui. Overexpression of PCDHB9 is correlated with tumor progression in esophageal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 612.
Current Concepts of Jaundice, with Particular Reference to Hepatitis
Authors: Lawrence E. Young
Journal: New England Journal of Medicine (1947)

JAUNDICE — or yellow staining of the skin, mucous membranes and scleras due to the presence of excessive amounts of bilirubin in the blood — can probably be produced by as great a variety of pathologic processes as any physical finding encountered in the practice of medicine.1 2 3 4 Since bilirubin is derived from hemoglobin, an understanding of the numerous mechanisms by which jaundice may develop is best approached by a review of certain aspects of the normal metabolism of hemoglobin.Normal Bile-Pigment MetabolismAs shown in Figure 1, the porphyrin rings of the hemoglobin molecule are made up of four pyrrol nuclei . . .
Myelodysplastic syndrome
Authors: C V Dang
Journal: JAMA (1992)

<h3>CASE PRESENTATION</h3> —Lawrence Nair, MD A 54-YEAR-OLD white man was referred to The Johns Hopkins Hospital because of refractory anemia. In 1988, anemia and neutropenia were noted, and in July 1990 he was admitted to another hospital, with a hemoglobin level of 55 g/L. Bone marrow biopsy revealed myeloid hyperplasia, and the proportion of blast cells was 0.02 to 0.03. The patient was thought to have a myelodysplastic disorder, and was given weekly transfusions of packed red blood cells (RBCs). In August 1990, the patient was referred to the National Institutes of Health for a second opinion. Bone marrow biopsy was repeated, and the findings were thought to be consistent with myelofibrosis. He was started on a trial course of danazol, as well as cyanocobalamin, pyridoxine hydrochloride, and folic acid. However, in September, the patient was readmitted with severe pain in the left upper quadrant of the abdomen, and a
THE SIGMUND POLLITZER LECTURESHIP
Journal: British Journal of Dermatology (1951)

British Journal of DermatologyVolume 63, Issue 5 p. 195-195 THE SIGMUND POLLITZER LECTURESHIP First published: May 1951 https://doi.org/10.1111/j.1365-2133.1951.tb13711.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume63, Issue5May 1951Pages 195-195 RelatedInformation
MOLECULAR ANALYSIS OF PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA LEG TYPE AT DIAGNOSIS AND RELAPSE - IMPLICATIONS FOR TARGETED THERAPIES
Authors: A. M. R. Schrader, R. A. L. de Groen, R. Willemze, P. M. Jansen, K. D. Quint, A. H. G. Cleven, T. van Wezel, R. van Eijk, D. Ruano, C. P. Tensen, E. Hauben, S. Woei-A-Jin, A. M. Busschots, M. H. Vermeer, J. S. P. Vermaat
Journal: HemaSphere (2019)
Fumonisin B 1 Carcinogenicity in a Two-Year Feeding Study Using F344 Rats and B6C3F 1 Mice
Authors: Paul C. Howard, Robert M. Eppley, Michael E. Stack, Alan Warbritton, Kenneth A. Voss, Ronald J. Lorentzen, Robert M. Kovach, Thomas J. Bucci
Journal: Environmental Health Perspectives (2001)
MEDICINE'S DEBT TO 19TH CENTURY CHEMISTRY
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE BILLINGS MURDER TRIAL. A MEDICO-LEGAL QUESTION
Authors: D. M. WICK
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P14.25 18F-fluordesoxyglucose positron emission tomography (FDG-PET/CT) the detection of the primary lesion and staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS)
Authors: F. Wolpert, E. Le Rhun, A. Berghoff, E. Rushing, N. Andratschke, L. Regli, N. Reyns, P. Kaufmann, M. Preusser, M. Weller
Journal: Neuro-Oncology (2017)

Background: In 30% of patients with brain metastasis (BM), BM are the first clinical manifestation of systemic malignancy, referred to as BM from cancer of unknown primary site (BM-CUPS). The value of 18F-fluordesoxyglucose positron emission tomography (FDG-PET)/CT in the work-up of BM-CUPS patients remains to be defined. Patients and methods: We screened 566 patients operated for BM at the University Hospital Zurich between 2004 and 2014 and identified 127 BM-CUPS patients. Two validation cohorts (n=100 and 120 patients) from independent centers were available. Results: FDG-PET/CT was not superior to CT in localizing the primary lesion as CT (FDG-PET/CT: 73/78, 93.6%; CT: n=70/78, 89.7%; p=0.25, McNemar’s test). Thirty-six of 64 patients (56.3%) showed the same result in spotting the primary tumor and other extracranial lesions. FDG-PET/CT identified additional lesions suspicious for extracranial metastases in 28 patients (43.7%). The graded prognostic assessment (GPA) score was determined post-hoc to objectify clinical relevance of additional findings. Information from CT alone or FDG-PET/CT was used to assess extracranial metastases. Median GPA was 3 for CT vs. 2.5 for PET/CT (p= 3.8x10-5), resulting in a predicted survival of 5.3 vs. 3.8 months (p= 6.1x10-5; Wilcoxon’s test). Sensitivity of CT and FDG-PET/CT and staging capabilities were comparable in all cohorts. Conclusions: FDG-PET/CT shows similar sensitivity to detect the primary tumor in BM-CUPS patients as CT, but improves the accuracy of staging. GPA scores and predicted survival differ significantly when calculated based on CT versus FDG-PET/CT. FDG-PET/CT should be prioritized for planning the diagnostic algorithm of BM-CUPS patients and redundant CT imaging should be avoided. Further, randomized trials on BM patients should consider stratification for the respective staging methods when employing GPA scores.
Abstract 998: HEx: A computational and synthetic biology platform applied to oncology drug discovery
Authors: Ulrich Schlecht, Pablo Cordero, Maureen Hillenmeyer, Ju Eun Jeon, Dan Kvitek, Brian Naughton, Philipp Wiemann, Colin Harvey
Journal: Cancer Research (2019)

Abstract We present a computational and synthetic biology platform for producing novel compounds targeting proteins relevant to oncology. As eukaryotes, fungi share approximately one third of human genes, including many relevant to core metabolism, cell cycle, DNA repair, and protein degradation. We have developed a computational method for mining fungal genomes to identify genes likely to produce compounds that inhibit specific human target proteins, including undruggable targets such as protein-protein interactions. We engineer these genes using our synthetic biology pipeline to produce the novel compounds in a heterologous host. We present in vitro data for an Aurora Kinase (AURKA) inhibitor developed using this platform as proof of concept for Hexagon Bio's pipeline. These data demonstrate the potential of this system to target the more than 6000 genes shared between fungi and humans. Citation Format: Ulrich Schlecht, Pablo Cordero, Maureen Hillenmeyer, Ju Eun Jeon, Dan Kvitek, Brian Naughton, Philipp Wiemann, Colin Harvey. HEx: A computational and synthetic biology platform applied to oncology drug discovery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 998.
Highlights
Journal: JAMA Internal Medicine (2018)

Li and colleagues performed a randomized clinical trial to compare the effectiveness of a tai ji quan intervention with multimodal exercise and stretching exercise in reducing falls in older adults who had fallen in the past year.The study involved 670 community-dwelling adults 70 years or older who were randomly allocated to 1 of 3 interventions, all of which involved a 60-minute exercise session twice weekly for 24 weeks.For older adults at high risk for falls, a therapeutically tailored tai ji quan balance training intervention was more effective than conventional exercise approaches for reducing the incidence of falls.Continuing Medical Education jamanetwork.com/learning LESS IS MORE Shared Decision Making for Lung Cancer Screening 1311In this qualitative content analysis of 14 recorded and transcribed outpatient clinical encounters, Brenner and colleagues assessed the quality of shared decision making about the initiation of lung cancer screening (LCS) in clinical practice.Results showed that of the 14 identified conversations between physicians and patients about initiation of LCS, none met the minimum skill criteria for 8 of 12 items on the Observing Patient Involvement in Decision Making scale, discussion of harms was nearly absent, and there was no evidence that decision aids or other patient education materials for LCS were used.Redberg provides an Editorial, and Ebell and Lin provide the Invited Commentary.
Correction to: Infection-related ventilator-associated complications in ICU patients colonised with extended-spectrum β-lactamase-producing Enterobacteriaceae
Authors: François Barbier, Sébastien Bailly, Carole Schwebel, Laurent Papazian, Élie Azoulay, Hatem Kallel, Shidasp Siami, Laurent Argaud, Guillaume Marcotte, Benoît Misset, Jean Reignier, Michaël Darmon, Jean‑Ralph Zahar, Dany Goldgran‑Toledano, Étienne de Montmollin, Bertrand Souweine, Bruno Mourvillier, Jean‑Francois Timsit
Journal: Intensive Care Medicine (2018)
Lumbar puncture
Authors: E. Alexander
Journal: JAMA (1967)

The technique of lumbar puncture was described by Quincke more than 75 years ago.<sup>1(p309-312)</sup>This method, therefore, has been available to the practitioner of medicine for three quarters of a century and has achieved increasing importance in medical diagnosis and treatment. Originally, lumbar puncture was conceived as a means of treating hydrocephalus and for the detection of tuberculosis of the central nervous system. The brilliance of the discovery by Quincke is obvious. A translation of the description of his technique, and a subsequent description of the dynamics of the cerebrospinal fluid by Queckenstedt, some 30 years later,<sup>1(p301-308)</sup>have become available recently in Wilkins'<i>Neurosurgical Classics</i>for English-speaking physicians. Quincke could have had little concept of the increasing value of his discovery in 1882, since many of the uses to which the technique have been put have necessarily awaited other broad discoveries and the development of new concepts of
Venous Thromboembolic Disease
Authors: Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Tanya Siddiqi, Judy L. Smith, Gary C. Yee, Anaadriana Zakarija, Nicole McMillian, Maoko Naganuma
Journal: Journal of the National Comprehensive Cancer Network (2013)

Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.
Mindfulness for Those with COPD, Asthma, Lung Cancer, and Lung Transplantation
Authors: Ni-Cheng Liang, Tania Von Visger, Asha Devereaux
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

"Mindfulness for Those with COPD, Asthma, Lung Cancer, and Lung Transplantation." American Journal of Respiratory and Critical Care Medicine, 202(4), pp. P11–P12
Aminophylline Dosage
Authors: Miles Weinberger
Journal: JAMA (1978)

<h3>To the Editor.—</h3> The report by Zaske et al (237:1453-1455, 1977) results in average dosages quite similar to those recently reported by Wyatt et al.<sup>1</sup>I think it needs to be strongly emphasized, however, that the average dosage requirements place up to 20% of patients at risk for serum concentrations in excess of 20 μg/ml, thus exposing the patients to potential toxicity.<sup>2</sup>I would therefore recommend that initial therapy be begun at lower dosages and that the average dosage requirements in the publication by Zaske et al be used as upper limits for dosage when serum concentrations are not monitored. The potential risk of using trough serum concentrations was also not mentioned by the authors. Particularly among children, peak serum concentrations estimated at two hours after a dose have been demonstrated to exceed predose trough levels by 9 ±3 μg/ml (mean ± 1 SD).<sup>3</sup> Appreciation of these
A Treatise on Massage. Theoretical and Practical; Its History, Mode of Application and Effects. Indications and Contra-Indications, with results of over fifteen hundred cases, by Douglas Graham, M.D.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Frank Netter, MD: 'command performance' in medical art
Authors: H. Cole
Journal: JAMA (1986)

Virtually every medical student has at some time wished for the ability to preserve on paper that which he or she sees in the laboratory or clinic. Whether it is a stage in the dissection of a cadaver, a pathology specimen, a histologic section, or an unusual finding during a physical examination, the desire to capture an observation, before it fades, is compelling. One young medical student in the late 1920s was uniquely capable of synthesizing the medical knowledge he was accumulating and then of rendering these complex facts in an astonishingly clear pictorial representation. To the satisfaction of thousands of subsequent students and physicians, he has continued to practice his art of medicine to this very day. The artist is Frank H. Netter, MD, whose 80th birthday anniversary coincides with the date (April 25) of this issue ofThe Journal. Netter still is busy illustrating the<i>CIBA Collection of</i>
Elevated Serum HER-2/<i>neu</i> Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast Cancer
Authors: Allan Lipton, S.M. Ali, K. Leitzel, L. Demers, V. Chinchilli, L. Engle, Harold A. Harvey, C. Brady, C.M. Nalin, M. Dugan, W. Carney, J. Allard
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To determine the effect of elevation of serum HER-2/neu on response to hormone therapy. PATIENTS AND METHODS: Seven hundred nineteen metastatic patients with estrogen receptor–positive (ER + ), progesterone receptor–positive, or both or ER status unknown breast cancer were randomized in three independent clinical trials to receive second-line hormone therapy with either megestrol acetate or an aromatase inhibitor (fadrozole or letrozole). An automated enzyme-linked immunosorbent assay specific for the extracellular domain of the HER-2/neu (c-erbB-2) oncoprotein product was used to detect serum levels. RESULTS: Two hundred nineteen patients (30%) had elevated serum HER-2/neu protein levels, using the mean + 2 SD (15 ng/mL) from the serum of healthy women as an upper limit. Response to treatment was available for 711 patients. The response rate (complete responses plus partial responses plus stable disease) to endocrine therapy was 45% in 494 patients with nonelevated and 23% in 217 patients with elevated serum HER-2/neu levels (P &lt; .0001). Median duration of treatment response (using the time to progression [TTP] variable for patients who responded) was shorter in the group with elevated serum HER-2/neu levels (11.7 months) compared with the patient group with nonelevated levels (17.4 months). TTP, time to treatment failure, and median survival (17.2 months v 29.6 months) were also significantly shorter in the patients with elevated serum HER-2/neu levels (P &lt; .0001). CONCLUSION: Patients with ER + and serum HER-2/neu-positive metastatic breast cancer are less likely to respond to hormone treatment and have a shorter duration of response than ER + and serum HER-2/neu–negative patients. Their survival duration is also shorter.
DR. JOHN H. RAUCH.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal